Polycythemia vera (PV) is a rare myeloproliferative neoplasm with no approved therapy that directly targets hematocrit, leaving patients dependent on repeated therapeutic phlebotomies. Merck KGaA, Darmstadt, Germany announced on October 19, 2026, a definitive agreement to acquire Silence Therapeutics plc for an equity value of approximately $1.3 billion, adding Divesiran®, a short interfering RNA (siRNA) targeting TMPRSS6, as its lead Phase 3-ready asset for PV.
The acquisition close, targeted for Q1 2027, requires shareholder approval and sanction by the High Court of Justice of England and Wales. Phase 3 initiation is planned for the first half of 2027.
Key Insights: Contract labs entering Divesiran® programs ahead of Phase 3 must prioritize GLP-compliant pharmacokinetics (PK) and pharmacodynamics (PD) platforms and GalNAc-siRNA bioanalytical method validation before enrollment opens.
Which Bioanalytical Capabilities Must Labs Qualify for siRNA Programs?
Divesiran® is a GalNAc (N-acetylgalactosamine)-conjugated siRNA administered subcutaneously once every three months via the mRNAi GOLD™ platform. GalNAc conjugation directs the siRNA to liver hepatocytes via the asialoglycoprotein receptor (ASGPR), silencing TMPRSS6 to reduce hepcidin suppression and restrict iron availability for red blood cell overproduction. These programs demand upstream quality standards spanning supply continuity, purity documentation, and sequence fidelity, as GalNAc-siRNA CMC case studies document.
Each capability addresses a distinct analytical gap in a GalNAc-siRNA program:
- LC-MS/MS quantitation: Distinguishing the antisense strand, sense strand, and GalNAc-conjugated parent compound from nuclease degradation products requires ion-pairing reversed-phase or hybrid LC-MS/MS workflows.
- Tissue distribution: Hematopoietic tissue bioanalysis may be needed to characterize PD endpoints, as liver-targeted siRNAs accumulate preferentially in hepatocytes.
- Immunogenicity assays: Anti-drug antibody (ADA) testing for GalNAc-siRNA conjugates requires platform-specific bridging assay designs that differ methodologically from standard protein biologic approaches.
- PD biomarker quantitation: Hepcidin protein levels serve as a key PD endpoint, requiring a validated ligand binding assay (LBA) or mass spectrometry method meeting the FDA Bioanalytical Method Validation guidance.
CROs supporting these capabilities must hold GLP compliance under 21 CFR Part 58 for toxicokinetic and safety pharmacology studies. They must also align with the ICH M3(R2) guideline governing the timing of nonclinical safety studies relative to clinical progression. Labs building investigational new drug (IND) packages for this modality can use regulated nonclinical submission standards as a framework for what regulators will require.
What Do Divesiran®’s FDA Designations Mean for Contract Labs?
Divesiran® holds FDA Fast Track designation and FDA Orphan Drug designation for PV, plus EC Orphan Drug designation granted on the recommendation of the European Medicines Agency (EMA). Together, these milestones compress testing timelines across the program’s supply chain.
| Regulatory Parameter | Status | Lab Implication |
| FDA Fast Track Designation | Granted (PV) | Rolling CMC review; sponsors impose accelerated IND-enabling timelines. |
| FDA Orphan Drug Designation | Granted (PV) | Seven-year exclusivity; method validation schedules may compress. |
| EC Orphan Drug Designation | Granted (PV) | EU partners must align with EMA clinical trial requirements concurrently with US Phase 3 protocol development. |
| SANRECO Phase 2 Primary Endpoint | Met (88% vs. 19% placebo; p<0.0001) | Phase 3 initiation planned H1 2027; GalNAc-siRNA methods need pre-enrollment validation. |
| Acquisition Close Target | Q1 2027—subject to shareholder approval and sanction by the High Court of Justice of England and Wales | Labs targeting this program should begin method development now. |
Iain Ross, interim principal executive officer and chairman of the Silence Therapeutics plc board, states: “This transaction follows potentially best-in-class Phase 2 polycythemia vera data for Divesiran® and reflects the important progress we have made advancing our differentiated siRNA pipeline.”
The Phase 2 SANRECO trial enrolled 48 phlebotomy-dependent PV patients in a 36-week, randomized, double-blind, placebo-controlled study. Divesiran® met its primary endpoint with an 88% responder rate versus 19% for placebo (p<0.0001), defined as maintaining hematocrit below 45% without phlebotomy during weeks 18–36. Mean phlebotomies fell to 0.2 per patient versus 2.1 on placebo over weeks 0–36 (p<0.0001), with investigators reporting no new safety findings.
Divesiran® Phase 3 Timeline and Lab Readiness for siRNA Programs
Labs engaged in RNA and molecular assay qualification for rare hematology programs face small patient populations, tight assay validation ranges, and accelerated IND timelines.
Mid-study supplier transitions at Phase 3 scale trigger revalidation under good manufacturing practice (GMP) frameworks, delaying data packages and IND submission timelines. Labs without qualified GalNAc-siRNA capabilities face a narrowing window before enrollment locks their options.
Sponsors may verify that candidate labs hold ISO/IEC 17025 or GLP certification and LC-MS/MS siRNA quantitation methods covering plasma and liver tissue matrices. Connect with accredited labs specializing in rare disease hematology outsourcing to build defensible analytical packages before enrollment opens.
Submit a free lab request to identify qualified partners on the Contract Laboratory network.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.